Dapagliflozin and cardiovascular outcomes in type 2
|
|
- Edgar Neal
- 5 years ago
- Views:
Transcription
1 EARN 3 FREE CPD POINTS diabetes Leader in digital CPD for Southern African healthcare professionals Dapagliflozin and cardiovascular outcomes in type 2 diabetes Introduction People with type 2 diabetes (T2D) are at high risk for adverse cardiovascular (CV) outcomes and progressive decline in renal function. In comparison with the general population, they are 2 to 4 times more likely to be hospitalised or to die from CV causes, including atherosclerotic CV disease (ASCVD) and heart failure. 1-3 Approximately one third of patients with T2D who develop heart failure have no history of prior coronary heart disease, and while careful control of modifiable CV risk factors can ameliorate risk of death, myocardial infarction (MI) and stroke, the incidence of heart failure in T2D remains consistently higher than that of matched controls. 2,3 Therefore, prevention and treatment of these CV complications is fundamental to the management of T2D. Until recently, the primary requirement for trials of drug therapy for T2D has been to show glucose-lowering efficacy and safety. However, concerns over the CV safety of some more recently introduced antihyperglycaemic agents prompted the US Food and Drug Administration (FDA) to mandate that from 2008 all new drugs should also be tested for CV safety. 4 Furthermore, in the light of data from these CV outcomes trials, new 2018 recommendations for antihyperglycaemic therapy for adults with T2D include early incorporation of an agent proven to reduce major adverse CV events (MACE) and/or CV mortality. 5 Most CV outcomes trials have shown a neutral effect of antihyperglycaemic agents on CV events. However, well powered randomised controlled trials have demonstrated that the sodium-glucose co-transporter-2 (SGLT-2) inhibitors have favourable effects on CV and renal outcomes, which remain consistent across a broad range of patient subgroups. 4,6-8 The most recent of these studies is the Dapagliflozin Effect on Cardiovascular Events - Thrombolysis in Myocardial Infarction 58 (DECLARE- TIMI 58) trial, which was designed to evaluate the effects of dapagliflozin on CV and renal outcomes in a broad population of patients with T2D, including those with or without ASCVD. 8 The results of DECLARE-TIMI 58, which are summarised in this article, were presented at the 2018 Scientific Sessions of the American Heart Association in November. 9 Previous studies to evaluate CV benefits of SGLT-2 inhibitors This report was made possible by an unrestricted educational grant from Astrazeneca. The content of the report is independent of the sponsor. Empagliflozin The prospective, randomised EMPAREG trial (Empagliflozin, Cardiovascular outcomes, and mortality in Type 2 Diabetes) published in 2015 was the first to demonstrate that SGLT-2 inhibitors may be associated with significant and important CV benefits. It compared once daily empagliflozin to placebo in addition to standard diabetes care in adults with T2D and established ASCVD (MI, december 2018 I 1
2 coronary artery disease, unstable angina, stroke or occlusive peripheral artery disease). 6 The median duration of treatment was 2.6 years and median observation time was 3.1 years. The primary outcome, a composite of death from CV causes, nonfatal MI (excluding silent MI) or nonfatal stroke, occurred in 10.5% of patients treated with empagliflozin compared with 12.1% in the placebo group (HR: 0.86, 95%CI: ; P=0.04 for superiority). Rates of MI and stroke did not differ between groups, but in comparison with placebo, death from CV causes, hospitalisation for heart failure and all-cause mortality were reduced by 38%, 35% and 32% respectively among patients assigned to empagliflozin. Earn free CPD Points Join our CPD community at and start to earn today! Canagliflozin Similar results were observed in the Canagliflozin Cardiovascular Assessment (CANVAS) program, which integrated data from two studies comparing canagliflozin to placebo in more than patients with T2D and CV risk. 7 Approximately three quarters of the subjects had a history of atherosclerotic vascular disease (coronary, cerebrovascular or peripheral) and two thirds had a history of CVD. Over a mean followup period of 188 weeks, the primary Dapagliflozin A large prespecified meta-analysis of data from 21 dapagliflozin studies including patients, 30% of whom had a history of CVD, indicated that overall dapagliflozin was associated with a 23% reduction in risk of MACE (composite of CVD death, MI and stroke). 10 In individuals with a history of CVD, the risk of MACE was reduced by 20%. Similar outcomes were observed in a large retrospective observational analysis (CVD-REAL Nordic) that evaluated data from more than patients with T2D treated in real-world clinical practice with either an SGLT-2 inhibitor (n=22 830) or other glucose lowering drugs (n=68 490). The vast majority of patients on SGLT-2 inhibitors were treated with dapagliflozin (94%), whereas only 5% and 1% received empagliflozin or canagliflozin, respectively. The mean age at baseline was 61 years and prevalence of CVD was 25%. SGLT-2 inhibitors were associated with significantly decreased risks of CV mortality (relative risk reduction (RRR): 47%), MACE (RRR: 22%), hospitalisation for heart failure (RRR: 30%) and a decreased of severe hypoglycaemia (RRR: 24%). The risk reduction outcome comprising a composite of death from CV causes, nonfatal MI or nonfatal stroke was significantly reduced by 14% in the canagliflozin group. However, in this group there was also an increased risk of amputation, primarily at the level of the toe and metatarsal (6.3 vs 3.4 per patient years; HR: 1.97; 95%CI: ). Nevertheless, the results of CANVAS suggested that CV protection may be a class effect of the SGLT2 inhibitors. for CV mortality was similar in patients with or without a history of CVD, but the risk reduction for MACE was significantly greater among individuals with a history of CVD (HR: 0.7 for those with a history of CVD, HR: 0.90 for those without). 11 In an analysis of data from the same study, CV outcomes were compared for new users of dapagliflozin (n=10 227) versus new users of DPP-4 inhibitors (n=30 681), among whom 23% had established CVD at baseline. Treatment with dapagliflozin was associated with a significantly lower risk of MACE (21%), hospitalisation for heart failure (38%) and all-cause mortality (41%). 12 Because most of the patients in CVD-REAL Nordic were treated with dapagliflozin, the results of the study supported evidence for a possible class effect of SGLT-2 inhibitors on CV outcomes. However, in comparison with EMPAREG and CANVAS, this population was notable for a substantially lower CV risk profile at baseline, indicating that the beneficial effects may be extrapolated to patients with a much broader CV risk profile I december 2018
3 DECLARE-TIMI 58 Study design and baseline characteristics DECLARE-TIMI 58 was a randomised, double-blind, multinational, placebocontrolled phase 3 study in which patients with T2D and established ASCVD (secondary prevention; n=6 974) or multiple CV risk factors (primary prevention; n=10 186) were randomised to dapagliflozin 10mg daily or placebo in addition to other treatments as usual. 8,9 Usual treatment was at the discretion of the treating physician. Inclusion criteria are listed in Table 1. After randomisation, the patients were followed up in person every 6 months and by telephone every 3 months in between clinic visits. The principle primary outcome of DECLARE-TIMI 58 was to demonstrate safety of treatment with dapagliflozin with respect to MACE. Additional prespecified primary and secondary endpoints relating to safety and efficacy are listed in Table 2. Table 1. DECLARE-TIMI 58 study inclusion criteria 8 Diagnosis of T2D 40 years of age HbA1c 6.5 and <12% CrCl 60ml/min/1.73m 2 AND Established ASCVD (secondary prevention) Ischaemic heart disease Cerebrovascular disease Peripheral artery disease OR Multiple CV risk factors (primary prevention) Men 55 years and women 60 years with at least one additional risk factor: Table 2. DECLARE-TIMI 58 study prespecified endpoints 8 Primary endpoints Safety (noninferiority versus placebo): 1. MACE: CV death, MI or ischaemic stroke Efficacy (superiority versus placebo): 1. MACE 2. Composite of CV death or hospitalisation for heart failure Secondary endpoints 1. Renal composite outcome: sustained decrease of 40% in egfr to <60ml/min/1.73m 2, new end-stage renal disease or death from renal or CV causes 2. Death from any cause 3. Sustained decrease of 40% in egfr to <60ml/min/1.73m 2, new end-stage renal disease or death from renal causes Dyslipidaemia Hypertension Current tobacco use CrCl: creatinine clearance; ASCVD: atherosclerotic cardiovascular disease Patients were followed up for a median of 4.2 years (interquartile range years). An overview of baseline characteristics and medications is shown in Table 3. december 2018 I 3
4 Table 3. DECLARE-TIMI 58 study baseline characteristics (full cohort; N=17 160) 8 Age (mean) 64 years Female/male 37%/63% Body mass index (mean) 32kg/m 2 HbA1c (mean) 8.3% Duration of diabetes (median; interquartile range) 11 years; 6-16 years egfr (mean) 85.2ml/min/1.73m 2 egfr 60 to <90ml/min/1.73m 2 45% Secondary prevention cohort (established ASCVD) 41% Primary prevention cohort (multiple risk factors) 59% History of heart failure 10% Medications Metformin 82% Insulin 41% Sulfonylurea 43% DPP-4 inhibitor 17% GLP-1 receptor agonist 4% Antiplatelet agents 61% ACE inhibitor or ARB 81% Beta-blocker 53% Statin or ezetimibe 75% Diuretics 41% egfr: estimated glomerular filtration rate; DPP-4: dipeptidyl peptidase-4; GLP-1: glucagon-like peptide-1; ACE: angiotensin converting enzyme; ARB: angiotensin receptor blocker Earn free CPD Points Join our CPD community at and start to earn today! Outcomes Cardiovascular risk factors In comparison with placebo, HbA1c levels were lower in the dapagliflozin group throughout the trial (average leastsquares mean absolute difference between the groups: 0.42%; 95%CI: 0.40 to 0.45). During the course of the study, body weight declined from a mean baseline of 91kg in both groups with significantly greater weight loss in the dapagliflozin group. At 48 months follow up, mean body weight was 89kg in the placebo group and 87kg in the dapagliflozin group (mean difference 1.8kg (95%CI: kg)). Blood pressure was also reduced significantly more in the dapagliflozin group. At 48 months, mean systolic blood pressure (SBP) was 135mmHg in the placebo group and 132mmHg in the dapagliflozin group (mean difference 2.7mmHg; 95%CI: mmHg); and mean diastolic blood pressure (DBP) was 76mmHg in both groups, with a mean difference of 0.7mmHg (95%CI: mmHg) in favour of dapagliflozin. 4 I december 2018
5 Cardiovascular and renal outcomes Cardiovascular and renal outcomes are listed in Table 4. The rate of MACE was similar in the placebo and dapagliflozin groups, with dapagliflozin meeting the prespecified criteria for noninferiority (P<0.001). The incidence of composite outcome of CV death or hospitalisation for heart failure was significantly lower in the dapagliflozin group. This was primarily consequent to a lower rate of hospitalisation for heart failure in this group, whereas there was no significant difference in the rate of CV death. In subgroup analysis, the benefit of dapagliflozin in terms of rate of CV death or hospitalisation for heart failure was maintained across subgroups, including primary vs secondary prevention, history of heart failure (yes or no) and egfr ( 90, 60 to <90, and <60ml/min/1.73m 2 ). Table 4. DECLARE-TIMI 58 study cardiovascular and renal outcomes 8 Statistically significant differences are bold Endpoint Placebo Dapagliflozin Hazard ratio MACE Overall 8.8% 9.4% 0.93 (95%CI: ) ASCVD subgroup 15.3% 13.9% 0.90 (95%CI: ) Multiple risk factor subgroup 5.3% 5.2% 1.01 (95%CI: ) CV death or hospitalisation Overall 5.8% 4.9% 0.83 (95%CI: ) ASCVD subgroup 9.2% 7.8% 0.83 (95%CI: ) Multiple risk factor subgroup 3.4% 2.8% 0.84 (95%CI: ) History of heart failure 19.7% 16.6% 0.79 (95%CI: ) No history of heart failure 4.2% 3.6% 0.84 (95%CI: ) egfr 90ml/min/1.73m 2 3.9% 4.0% 0.96 (95%CI: ) egfr 60 to <90ml/min/1.73m 2 6.5% 5.2% 0.79 (95%CI: ) egfr <60ml/min/1.73m % 9.0% 0.78 (95%CI: ) Hospitalisation for heart failure Overall 3.3% 2.5% 0.73 (95%CI: ) ASCVD subgroup 9.3% 7.8% 0.83 (95%CI: ) Multiple risk factor subgroup 3.4% 2.8% 0.84 (95%CI: ) CV death 2.9% 2.9% 0.98 (95%CI: ) 40% decrease in egfr to <60ml/min/1.73m 2, ESRD, or death from renal or CV causes 40% decrease in egfr to <60ml/min/1.73m 2, ESRD, or death from renal causes 5.6% 4.3% 0.76 (95%CI: ) 2.8% 1.5% 0.53 (95%CI: ) Death from any cause 6.6% 6.2% 0.93% (95%CI: ) MACE: major adverse cardiovascular event; ASCVD: atherosclerotic cardiovascular disease; CV: cardiovascular; ESRD: end-stage renal disease december 2018 I 5
6 Safety of dapagliflozin Key safety findings are listed in Table 5. In general, individual adverse events were uncommon in both groups. Compared with placebo, dapagliflozin was associated with a significantly lower rate of treatment-emergent serious adverse events (SAE), major hypoglycaemia, acute renal injury and bladder cancer. The incidence of amputations and fractures, adverse events that had been flagged in previous studies with canagliflozin, was not significantly different in the dapagliflozin and placebo groups. Also, in contrast to findings in previous studies of SGLT-2 inhibitors, urinary tract infections and symptoms of volume depletion were not increased in the dapagliflozin group. In keeping with previous SGLT-2 inhibitor studies, adverse events that were more common with dapagliflozin included diabetic ketoacidosis and genital infections. Both were uncommon (27 and 76 patients respectively, out of patients receiving dapagliflozin) and more than 80% of patients who experienced diabetic ketoacidosis were using insulin at baseline. Although adverse events leading to discontinuation were more common with dapagliflozin than with placebo, overall fewer patients in the dapagliflozin group discontinued the assigned trial regimen prematurely (21.1% in the dapagliflozin group vs 25.1% in the placebo group). Table 5. DECLARE-TIMI 58 study: Key safety events 8 Event Placebo (%) (n=8 569) Dapagliflozin (%) (n=8 574) P value Less common in the dapagliflozin group Treatment emergent SAE <0.001 Major hypoglycaemia Acute kidney injury Bladder cancer More common in the dapagliflozin group Adverse event leading to discontinuation 6.9% 8.1% 0.01 Diabetic ketoacidosis Genital infection <0.001 No significant difference between groups Amputation Earn free CPD Points Join our CPD community at and start to earn today! Fracture Symptoms of volume depletion Urinary tract infection Hypersensitivity SAE: serious adverse events 6 I december 2018
7 DECLARE-TIMI 58 in context DECLARE-TIMI 58 is a large study in a diverse group of patients with T2D at high risk for CV events. However, in contrast to EMPAREG and CANVAS, it included a large proportion of patients with CV risk factors, but without established ASCVD. 6-8 Compared with placebo, dapagliflozin was associated with a lower rate of CV death or hospitalisation for heart failure, which remained consistent across this broad range of patients regardless of history of heart failure or ASCVD. 8 The implications from DECLARE- TIMI 58 that the benefits of SGLT-2 inhibitors observed in patients with T2D and ASCVD, particularly in relation to progression to heart failure and possibly also progression of renal disease, extend also to patients without established ASCVD have been validated in a recent meta-analysis of these three large outcomes studies. 13 Analysis of the combined data showed that the effect of SGLT-2 inhibitors on MACE was modest and confined to individuals with a history of ASCVD. However, SGLT-2 inhibitors were associated with significant reductions in risk of hospitalisation for heart failure, composite of hospitalisation for heart failure and CV death, and composite of worsening of renal function, end-stage renal disease or renal death, and these effects were similarly robust in patients with ASCVD and those with multiple risk factors, but without ASCVD (Table 6). The benefits in terms of hospitalisation for heart failure and composite renal endpoint (renal worsening, ESRD, or renal death) were present regardless of baseline renal function, but the magnitude of benefit was dependent on baseline renal function. Rate of hospitalisation for heart failure was reduced by 40% among those with an egfr <60ml/min/1.73m², by 31% in those with egfr 60 to <90ml/ min/1.73m², and by 12% (not significant) in patients with egfr 90ml/min/1.73m² (P value for interaction = 0.007). In contrast, reduction of progression of renal disease was greatest among individuals with preserved renal function at baseline (RRR: 33%, 44% and 56%, respectively; P value for interaction = 0.026). Table 6. Meta-analysis of combined data from EMPAREG, CANVAS and DECLARE-TIMI Outcome Hazard ratio (95%CI) Risk reduction vs placebo MACE: MI, stroke, CV death 0.89 ( ) 11% ASCVD a 0.86 ( ) c 14% Multiple risk factors (without ASCVD) b 1.00 ( ) c NS Hospitalisation for heart failure a 0.61 ( ) 31% Hospitalisation for heart failure and CV death 0.77 ( ) 23% ASCVD a 0.76 ( ) d 24% Multiple risk factors (without ASCVD) b 0.84 ( ) d NS History of heart failure a 0.71 ( ) e 29% No history of heart failure a 0.79 ( ) e 21% Composite of renal worsening, ESRD, or renal death 0.55 ( ) 45% ASCVD a 0.56 ( ) f 44% Multiple risk factors (without ASCVD) b 0.54 ( ) f 46% Fixed effects model; NS: not significant; ESRD: end-stage renal disease; a: includes data from EMPAREG, CANVAS and DECLARE-TIMI 58; b: includes data from CANVAS and DECLARE-TIMI 58; c: P for interaction 0.05; d: P for interaction 0.41; e: P for interaction 0.51; f: P for interaction 0.71 december 2018 I 7
8 Conclusions DECLARE-TIMI 58 adds to the growing evidence supporting the efficacy and safety of SGLT-2 inhibitors for treatment of T2D across a diverse patient population. Importantly, this class of drugs is associated with robust reductions in hospitalisation for heart failure and progression of renal disease, regardless of baseline atherosclerosis risk category or history of heart failure. 13 Consistent with previous studies of SGLT-2 inhibitors, DECLARE-TIMI 58 confirms that dapagliflozin has a favourable safety profile and significantly reduces CV risk factors important to patients with T2D, including HbA1c, blood pressure and weight gain. References Earn free CPD Points Are you a member of Southern Africa s leading digital Continuing Professional Development website earning FREE CPD points with access to best practice content? Only a few clicks and you can register to start earning today Visit For all Southern African healthcare professionals 1. Rawshani A, Rawshani A, Franzén S, et al. Mortality and cardiovascular disease in type 1 and type 2 diabetes. N Engl J Med 2017; 376: Rawshani A, Rawshani A, Franzén S, et al. Risk factors, mortality, and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 2018; 379: Khan H, Anker SD, Januzzi JL, et al. Heart failure epidemiology in patients with diabetes mellitus without coronary artery disease. J Card Fail Published online. pii: S (18) DOI: /j. cardfail Zelniker TA, Braunwald E. Cardiac and renal effects of sodium-glucose co-transporter 2 inhibitors in diabetes: JACC state-of-the-art review. J Am Coll Cardiol Published online. DOI: /j.jacc American Diabetes Association. Summary of revisions: Standards of medical care. In Standards of medical care in diabetes Diabetes Care 2018; 41(Suppl 1): 6. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes and mortality in type 2 diabetes. N Engl J Med 2015; 373: Neal B, Mahaffey KW, de Zeeuw D, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 2017; 377: Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med Published online 10 Nov DOI: /NEJMoa Wiviott SD. Dapagliflozin Effect on Cardiovascular Events Thrombolysis in Myocardial Infarction 58 - DECLARE- TIMI 58. Presentation at American Heart Association (AHA) Scientific Sessions, 10 Nov 2018, Chicago, IL, USA Sonesson C, Johansson PA, Johnsson E, et al. Cardiovascular effects of dapagliflozin in patients with type 2 diabetes and different risk categories: a metaanalysis. Cardiovasc Diabetol 2016; 15: Birkeland K, Jørgensen ME, Carstensen B, et al. Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis. Lancet Diab Endocrinol 2017; 5(9): Persson F, Nyström T, Jørgensen ME, et al. Dapagliflozin is associated with lower risk of cardiovascular events and all-cause mortality in people with type 2 diabetes (CVD-REAL Nordic) when compared with dipeptidyl peptidase-4 inhibitor therapy: A multinational observational study. Diab Obes Metab 2018; 20: Zelniker TA, Wiviott DSD, Raz I, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet 2018; (published online Nov 10.). DOI: /S (18)32590-X Find us at DeNovo Disclaimer The views and opinions expressed in the article are those of the presenters and do not necessarily reflect those of the publisher or its sponsor. In all clinical instances, medical practitioners are referred to the product insert documentation as approved by relevant control authorities. Published by denovo Medica Reg: 2012/216456/07 70 Arlington Street, Everglen, Cape Town, 7550 Tel: (021) I info@denovomedica.com 8 I december 2018
Top HF Trials to Impact Your Practice
Top HF Trials to Impact Your Practice Biykem Bozkurt, MD, FACC The Mary and Gordon Cain Chair & Professor of Medicine Medical Care Line Executive, DeBakey VA Medical Center, Director, Winters Center for
More informationCANVAS Program Independent commentary
CANVAS Program Independent commentary Cliff Bailey Aston University, Birmingham, UK 2017 Disclosures and disclaimers Clifford J Bailey CJB has attended advisory boards, undertaken ad hoc consultancy, received
More informationNo Increased Cardiovascular Risk for Lixisenatide in ELIXA
ON ISSUES IN THE MANAGEMENT OF TYPE 2 DIABETES JUNE 2015 Coverage of data from ADA 2015, June 5 9 in Boston, Massachusetts No Increased Cardiovascular Risk for Lixisenatide in ELIXA First Cardiovascular
More informationThe EMPA-REG OUTCOME trial: Design and results. David Fitchett, MD University of Toronto, Canada
The EMPA-REG OUTCOME trial: Design and results David Fitchett, MD University of Toronto, Canada Asian Cardio Diabetes Forum April 23 24, 2016 Kuala Lumpur, Malaysia Life Expectancy Is Reduced by ~12 Years
More informationCardiovascular Benefits of Two Classes of Antihyperglycemic Medications
Cardiovascular Benefits of Two Classes of Antihyperglycemic Medications Nathan Woolever, Pharm.D., Resident Pharmacist Pharmacy Grand Rounds November 6 th, 2018 Franciscan Healthcare La Crosse, WI 2017
More informationegfr > 50 (n = 13,916)
Saxagliptin and Cardiovascular Risk in Patients with Type 2 Diabetes Mellitus and Moderate or Severe Renal Impairment: Observations from the SAVOR-TIMI 53 Trial Supplementary Table 1. Characteristics according
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and
More informationEffect of SGLT-2 Inhibitors on the Heart. Robert Zimmerman MD Vice Chairman Endocrinology Director Diabetes Center Cleveland Clinic
Effect of SGLT-2 Inhibitors on the Heart Robert Zimmerman MD Vice Chairman Endocrinology Director Diabetes Center Cleveland Clinic Disclosures Speaker - Johnson and Johnson - Merck Research - Merck - Novo
More information01/09/2017. Outline. SGLT 2 inhibitor? Diabetes Patients: Complex and Heterogeneous. Association between diabetes and cardiovascular events
MICROVASCULAR COMPLICATIONS Incidence of outcome g 1 Cardioprotective Effects of SGLT2s Relevant for Which T2 Diabetes Patient? SGLT 2 inhibitor? 58 year old, waist circumference 5 cm, PMH: IHD On statin,
More informationSodium-Glucose Co-Transporter 2 (SGLT-2) Inhibitors Drug Class Prior Authorization Protocol
Sodium-Glucose Co-Transporter 2 (SGLT-2) Inhibitors Drug Class Prior Authorization Protocol Line of Business: Medicaid P&T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has
More informationDrug Class Monograph
Drug Class Monograph Class: Sodium-Glucose Co-Transporter 2 (SGLT-2) Inhibitors Drugs: Farxiga (dapagliflozin), Invokamet (canagliflozin/metformin), Invokana (canagliflozin), Jardiance (empagliflozin),
More informationEmpagliflozin (Jardiance ) for the treatment of type 2 diabetes mellitus, the EMPA REG OUTCOME study
Empagliflozin (Jardiance ) for the treatment of type 2 diabetes mellitus, the EMPA REG OUTCOME study POSITION STATEMENT: Clinicians should continue to follow MHRA advice and NICE technology appraisal guidance
More informationNew Strategies for Cardiovascular Risk reduction in Diabetes
New Strategies for Cardiovascular Risk reduction in Diabetes Dr. Godwin LEUNG Tat Chi MB ChB(HK), MRCP (UK), FHKCP, FHKAM (Medicine) FRCP (Glasg), FACC Specialist in Cardiology % event as first CV event
More informationHelp the Heart. An Update on GLP-1 Agonists and SGLT2 Inhibitors. Tara Hawley, PharmD PGY1 Pharmacy Resident Mayo Clinic Health System Eau Claire
Help the Heart An Update on GLP-1 Agonists and SGLT2 Inhibitors Tara Hawley, PharmD PGY1 Pharmacy Resident Mayo Clinic Health System Eau Claire Mayo Clinic Grand Rounds May 16, 2017 2017 MFMER slide-1
More informationManagement of Type 2 Diabetes Cardiovascular Outcomes Trials Tom Blevins MD Texas Diabetes and Endocrinology Austin, Texas
Management of Type 2 Diabetes Cardiovascular Outcomes Trials 2018 Tom Blevins MD Texas Diabetes and Endocrinology Austin, Texas Speaker Disclosure Dr. Blevins has disclosed that he has received grant support
More informationCan We Reduce Heart Failure by Treating Diabetes? CVOT Data on SGLT2 Inhibitors and GLP-1Receptor Agonists
Can We Reduce Heart Failure by Treating Diabetes? CVOT Data on SGLT2 Inhibitors and GLP-1Receptor Agonists Robert R. Henry, MD Professor of Medicine University of California, San Diego Relevant Conflict
More informationCardiologists and HbA1c: Novel Diabetes Drugs and Cardiovascular Disease Outcomes
Biomarkers 2018 Cardiologists and HbA1c: Novel Diabetes Drugs and Cardiovascular Disease Outcomes Gregg C. Fonarow, MD, FACC, FAHA, FHFSA Elliot Corday Professor of Cardiovascular Medicine UCLA Division
More informationUpdate on Diabetes Cardiovascular Outcome Trials
Update on Diabetes Cardiovascular Outcome Trials Jay S. Skyler, MD, MACP Division of Endocrinology, Diabetes, and Metabolism and Diabetes Research Institute University of Miami Miller School of Medicine
More informationUpdates in Diabetes and Cardiovascular Disease Management: Are You Making the Link?
Updates in Diabetes and Cardiovascular Disease Management: Are You Making the Link? Denise Kolanczyk, PharmD, BCPS AQ Cardiology 1 Erika Hellenbart, PharmD, BCPS 2 Jennifer D Souza, PharmD, CDE, BC ADM
More informationInvokana (canagliflozin) NEW INDICATION REVIEW
Invokana (canagliflozin) NEW INDICATION REVIEW Introduction Brand name: Invokana Generic name: Canagliflozin Pharmacological class: Sodium-glucose cotransporter 2 (SGLT2) inhibitor Strength and Formulation:
More informationDiabetes and New Meds for Cardiovascular Risk Reduction. F. Dwight Chrisman, MD, FACC. Disclosures: BI Boehringer Ingelheim speaker
Diabetes and New Meds for Cardiovascular Risk Reduction F. Dwight Chrisman, MD, FACC Disclosures: BI Boehringer Ingelheim speaker 1 Prevalence of DM DM state specific prevalence 2006 4%-6% 6-8% 8-10% 10-12%
More informationHeart Failure Management in T2 DM A Practical Approach. David Fitchett MD St Michael s Hospital Toronto
Heart Failure Management in T2 DM A Practical Approach David Fitchett MD St Michael s Hospital Toronto Faculty: Faculty Disclosure David Fitchett MD,, FRCP(C) Associate Professor of Medicine, University
More informationSGLT2 inhibition in diabetes: extending from glycaemic control to renal and cardiovascular protection
SGLT2 inhibition in diabetes: extending from glycaemic control to renal and cardiovascular protection Hiddo Lambers Heerspink Department of Clinical Pharmacy and Pharmacology University Medical Center
More informationpremix insulin and DPP-4 inhibitors what are the facts? New Sit2Mix trial provides first global evidence
Earn 3 CPD Points online Using a premix insulin (BIAsp 30) with a DPP-4 inhibitor what are the facts? New Sit2Mix trial provides first global evidence An important trial using a premix insulin (BIAsp 30)
More informationCardiovascular Outcomes With Newer Diabetes Drugs: Results From The EMPA-REG and LEADER Trials
Cardiovascular Outcomes With Newer Diabetes Drugs: Results From The EMPA-REG and LEADER Trials Rajiv Roy, MD Endocrinology Sharp Rees-Stealy Medical Group Background Between 1990 and 2010: Incidence of
More informationSodium-glucose cotransporter 2 inhibitors and death and heart failure in type 2 diabetes
Editorial Page 1 of 5 Sodium-glucose cotransporter 2 inhibitors and death and heart failure in type 2 diabetes Hidekatsu Yanai Department of Internal Medicine, National Center for Global Health and Medicine
More informationLEADER Liraglutide and cardiovascular outcomes in type 2 diabetes
LEADER Liraglutide and cardiovascular outcomes in type 2 diabetes Presented at DSBS seminar on mediation analysis August 18 th Søren Rasmussen, Novo Nordisk. LEADER CV outcome study To determine the effect
More informationLower Risk of Death With SGLT2 Inhibitors in Observational Studies: Real or Bias? Diabetes Care 2018;41:6 10
6 Diabetes Care Volume 41, January 2018 PERSPECTIVES IN CARE Lower Risk of Death With SGLT2 Inhibitors in Observational Studies: Real or Bias? Diabetes Care 2018;41:6 10 https://doi.org/10.2337/dc17-1223
More informationEmpagliflozin: Role in Treatment Options for Patients with Type 2 Diabetes Mellitus
Diabetes Ther (2017) 8:33 53 DOI 10.1007/s13300-016-0211-x REVIEW Empagliflozin: Role in Treatment Options for Patients with Type 2 Diabetes Mellitus John E. Anderson. Eugene E. Wright Jr.. Charles F.
More informationSGLT-2 inhibitors: Dapagliflozin is well tolerated in older individuals aged 75 years
Earn 3 CPD Points online SGLT-2 inhibitors: A perspective on safety and tolerability KEY MESSAGES Dapagliflozin is a new sodium glucose co-transporter-2 (SGLT-2) inhibitor for the treatment of type 2 diabetes
More informationThe Role Of SGLT-2 Inhibitors In Clinical Practice. Anne Peters, MD Professor, USC Keck School of Medicine Director, USC Clinical Diabetes Programs
The Role Of SGLT-2 Inhibitors In Clinical Practice Anne Peters, MD Professor, USC Keck School of Medicine Director, USC Clinical Diabetes Programs Disclosure of Potential Conflicts of Interest Consultantship
More informationDiscussant Primary and Secondary Prevention of CV Events in the CANVAS Program
Discussant Primary and Secondary Prevention of CV Events in the CANVAS Program M. Angelyn Bethel, MD Associate Professor of Diabetes and Endocrinology University of Oxford UK Aims & major findings Aims:
More informationThe Clinical Unmet need in the patient with Diabetes and ACS
The Clinical Unmet need in the patient with Diabetes and ACS Professor Kausik Ray (UK) BSc(hons), MBChB, MD, MPhil, FRCP (lon), FRCP (ed), FACC, FESC, FAHA Diabetes is a global public health challenge
More informationCanagliflozin for Primary and Secondary Prevention of Cardiovascular Events in Type 2 Diabetes: Results From the CANVAS Program
Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events in Type 2 Diabetes: Results From the CANVAS Program Kenneth W. Mahaffey, Bruce Neal, Vlado Perkovic, Dick de Zeeuw, Greg Fulcher,
More informationADVANCE post trial ObservatioNal Study
Hot Topics in Diabetes 50 th EASD, Vienna 2014 ADVANCE post trial ObservatioNal Study Sophia Zoungas The George Institute The University of Sydney Rationale and Study Design Sophia Zoungas The George Institute
More informationSoo LIM, MD, PHD Internal Medicine Seoul National University Bundang Hospital
Soo LIM, MD, PHD Internal Medicine Seoul National University Bundang Hospital Agenda Association between Cardiovascular Disease and Type 2 Diabetes Importance of HbA1c Management esp. High risk patients
More informationLATE BREAKING STUDIES IN DM AND CAD. Will this change the guidelines?
LATE BREAKING STUDIES IN DM AND CAD Will this change the guidelines? Objectives 1. Discuss current guidelines for prevention of CHD in diabetes. 2. Discuss the FDA Guidance for Industry regarding evaluating
More informationDisclosures. Diabetes and Cardiovascular Risk Management. Learning Objectives. Atherosclerotic Cardiovascular Disease
Disclosures Diabetes and Cardiovascular Risk Management Tony Hampton, MD, MBA Medical Director Advocate Aurora Operating System Advocate Aurora Healthcare Downers Grove, IL No conflicts or disclosures
More informationDiabetes at the limits
Earn 3 CPD Points online Extending the limits of diabetes care Diabetes at the limits KEY MESSAGES There is a very close relationship between the extent of hypoglycaemia and the failure of glucose lowering
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Proposed Health Technology Appraisal
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Proposed Health Technology Appraisal Dapagliflozin in combination therapy for the Final scope Remit/appraisal objective To appraise the clinical and
More informationCurrent principles of diabetes management
Current principles of diabetes management Prof. Martin Haluzík, MD, DSc. 3 Department of Medicine, General University Hospital and 1st Faculty of Medicine, Charles University in Prague, Czech Republic
More informationDiabetes new challenges, new agents, new order
Diabetes new challenges, new agents, new order Ken Earle St Georges University Hospitals NHS Foundation Trust Overview Cardiovascular disease unmet needs Treating evident and residual risk Integrating
More informationsitagliptin, 25mg, 50mg and 100mg film-coated tablets (Januvia ) SMC No. (1083/15) Merck Sharp and Dohme UK Ltd
sitagliptin, 25mg, 50mg and 100mg film-coated tablets (Januvia ) SMC No. (1083/15) Merck Sharp and Dohme UK Ltd 07 August 2015 The Scottish Medicines Consortium (SMC) has completed its assessment of the
More informationGLP 1 agonists Winning the Losing Battle. Dr Bernard SAMIA. KCS Congress: Impact through collaboration
GLP 1 agonists Winning the Losing Battle Dr Bernard SAMIA KCS Congress: Impact through collaboration CONTACT: Tel. +254 735 833 803 Email: kcardiacs@gmail.com Web: www.kenyacardiacs.org Disclosures I have
More informationThe Flozins Quest for Clarity?
The Flozins Quest for Clarity? Choosing Wisely with Academic Detailing 2018 ARE THEY THE REAL DEAL Disclosure statements The Academic Detailing Service is operated by Dalhousie Continuing Professional
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the
More informationSafety profile of Liraglutide: Recent Updates. Mohammadreza Rostamzadeh,M.D.
Safety profile of Liraglutide: Recent Updates Mohammadreza Rostamzadeh,M.D. Pancreatitis: Victoza post-marketing experience: spontaneous reports of pancreatitis For the majority of the cases, there is
More informationCanagliflozin in combination therapy for treating type 2 diabetes
Canagliflozin in combination therapy for treating type 2 Issued: June 2014 guidance.nice.org.uk/ta NICE has accredited the process used by the Centre for Health Technology Evaluation at NICE to produce
More informationWhen Statins Aren t Enough: Appropriate Therapies for High-Risk Patients with Diabetes
When Statins Aren t Enough: Appropriate Therapies for High-Risk Patients with Diabetes Kim K. Birtcher, MS, PharmD, AACC, FNLA, CLS, BCPS (AQ-Cardiology), CDE Clinical Professor University of Houston College
More informationOverview T2DM medications. Winnie Ho
Overview T2DM medications Winnie Ho Diabetes in Australia 1.7 million Australians with diabetes, of these 85% have T2DM 2-fold excess risk CV death in patients with diabetes Risk factor for progression
More informationCedars Sinai Diabetes. Michael A. Weber
Cedars Sinai Diabetes Michael A. Weber Speaker Disclosures I disclose that I am a Consultant for: Ablative Solutions, Boston Scientific, Boehringer Ingelheim, Eli Lilly, Forest, Medtronics, Novartis, ReCor
More informationA factorial randomized trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes
A factorial randomized trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes Hypotheses: Among individuals with type 2 diabetes, the risks of major microvascular
More informationMedical therapy advances London/Manchester RCP February/June 2016
Medical therapy advances London/Manchester RCP February/June 2016 Advances in medical therapies for diabetes mellitus Duality of interest: The speaker or institutions with which he is associated has received
More informationDiabetes and Heart Failure: The Role of SGLT2 Inhibitors
22 nd Annual Heart Failure 2018 Symposium Diabetes and Heart Failure: The Role of SGLT2 Inhibitors Gregg C. Fonarow, MD, FACC, FAHA, FHFSA Elliot Corday Professor of Cardiovascular Medicine UCLA Division
More informationESC GUIDELINES ON DIABETES AND CARDIOVASCULAR DISEASES
ESC GUIDELINES ON DIABETES AND CARDIOVASCULAR DISEASES Pr. Michel KOMAJDA Institute of Cardiology - IHU ICAN Pitie Salpetriere Hospital - University Pierre and Marie Curie, Paris (France) DEFINITION A
More informationClinical Relevance of Blood Pressure Lowering Effect of Modern Antidiabetic Drugs
Clinical Relevance of Blood Pressure Lowering Effect of Modern Antidiabetic Drugs Professor Guntram Schernthaner Medical University of Vienna, Austria guntram.schernthaner@meduniwien.ac.at Agenda Glucose
More informationNon-insulin treatment in Type 1 DM Sang Yong Kim
Non-insulin treatment in Type 1 DM Sang Yong Kim Chosun University Hospital Conflict of interest disclosure None Committee of Scientific Affairs Committee of Scientific Affairs Insulin therapy is the mainstay
More informationThe ABCs (A1C, BP and Cholesterol) of Diabetes
The ABCs (A1C, BP and Cholesterol) of Diabetes Gregg Simonson, PhD Director, Professional Training and Consulting International Diabetes Center; Adjunct Assistant Professor, University of Minnesota Department
More informationChallenges in type 2 diabetes control: slipping control and weight gain
control Earn 3 CPD Points online Case study Challenges in type 2 diabetes control: slipping control and weight gain Presenter Dr Sedeshan Govender Specialist Physician, Endocrinologist and Diabetologists
More informationLowering blood pressure (BP) in patients with type 2
Average Clinician-Measured Blood Pressures and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Ischemic Heart Disease in the EXAMINE Trial William B. White, MD; Fatima Jalil, MD;
More informationRetour sur le congrès de l AHA 2017
Retour sur le congrès de l AHA 2017 Paul Poirier MD, PhD, FRCPC, FACC, FAHA, FCCS Professeur Faculté de pharmacie Université Laval Responsable du programme de prévention/réadaptation cardiaque Canagliflozin
More informationPROTEZIONE DAL DANNO RENALE NEL DIABETE TIPO 2: RUOLO DEI NUOVI FARMACI. Massimo Boemi UOC Malattie Metaboliche e Diabetologia IRCCS INRCA Ancona
PROTEZIONE DAL DANNO RENALE NEL DIABETE TIPO 2: RUOLO DEI NUOVI FARMACI Massimo Boemi UOC Malattie Metaboliche e Diabetologia IRCCS INRCA Ancona Disclosure Dr Massimo Boemi has been granted as speaker
More informationHave you seen a patient like Elaine *?
(linagliptin) 5mg tablets Have you seen a patient like Elaine *? *Hypothetical patient profile Elaine * : 60 years old Housewife *Hypothetical patient profile ELAINE*: T2D Patient with early signs of kidney
More informationDapagliflozin and Outcomes in Patients with Peripheral Artery Disease: Insights from DECLARE-TIMI 58
Dapagliflozin and Outcomes in Patients with Peripheral Artery Disease: Insights from DECLARE-TIMI 58 Marc P. Bonaca MD MPH for the DECLARE TIMI 58 Investigators American College of Cardiology March 2019
More informationSGLT2 Inhibitors
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: SGLT2 Inhibitors Page: 1 of 7 Last Review Date: June 22, 2018 SGLT2 Inhibitors Description Invokana
More informationAdult Diabetes Clinician Guide NOVEMBER 2017
Kaiser Permanente National CLINICAL PRACTICE GUIDELINES Adult Diabetes Clinician Guide Introduction NOVEMBER 2017 This evidence-based guideline summary is based on the 2017 KP National Diabetes Guideline.
More informationHave you seen a patient like Carol *?
(linagliptin) 5mg tablets Have you seen a patient like Carol *? *Hypothetical patient profile Carol * : 70 years old Retired schoolteacher *Hypothetical patient profile CAROL*: T2D patient with moderate
More informationDrug Class Monograph
Drug Class Monograph Class: Dipeptidyl-Peptidase 4 (DPP-4) Inhibitors Drugs: alogliptin, alogliptin/metformin, Januvia (sitagliptin), Janumet (sitagliptin/metformin), Janumet XR (sitagliptin/metformin),
More informationBioresorbable polymer drug-eluting stents in PCI
EARN 3 FREE CPD POINTS CARDIOVASCULAR Leader in digital CPD for Southern African healthcare professionals The BIOFLOW-V trial, using the Orsiro ultrathin strut stent with biodegradable polymer, showed
More informationSGLT-2 INHIBITORS: CVD REDUCTION THROUGH DIURESIS
SGLT-2 INHIBITORS: CVD REDUCTION THROUGH DIURESIS Dr. Kirtida Acharya National chair, Diabetes Kenya Consultant Endocrinologist/Diabetologist, MP Shah Hospital KCS Symposium, 30 th June, 2017 Sarova Whitesands,
More informationNATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Single Technology Appraisal. Canagliflozin in combination therapy for treating type 2 diabetes
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Single Technology Appraisal Canagliflozin in combination therapy for Final scope Remit/appraisal objective To appraise the clinical and cost effectiveness
More informationCV outcomes Studies and Implications for diabetes management. Seraj Abualnaja, MD, FRCPC Consultant Interventional cardiologist DSFH
CV outcomes Studies and Implications for diabetes management Seraj Abualnaja, MD, FRCPC Consultant Interventional cardiologist DSFH Case 49 y female with the following medical problems DM typ2 Hypertension
More informationDrug Class Monograph
Class: Dipeptidyl-Peptidase 4 (DPP-4) Inhibitors Drug Class Monograph Drugs: alogliptin, Januvia (sitagliptin), Janumet (sitagliptin/metformin), Janumet XR (sitagliptin/metformin), Jentadueto (linagliptin/metformin),
More informationFarmaci innovativi e terapie di associazione: quali opportunità? Giuseppe Penno Dipartimento di Medicina Clinica e Sperimentale
Farmaci innovativi e terapie di associazione: quali opportunità? Giuseppe Penno Dipartimento di Medicina Clinica e Sperimentale Dichiarazione esplicita di trasparenza delle fonti di finanziamento e dei
More informationMacrovascular Residual Risk. What risk remains after LDL-C management and intensive therapy?
Macrovascular Residual Risk What risk remains after LDL-C management and intensive therapy? Defining Residual Vascular Risk The risk of macrovascular events and microvascular complications which persists
More informationSGLT2 and cardiovascular events: Why did EMPA-REG Outcomes surprise and what were the likely mechanisms? David Preiss, 3 John J McMurray 1
SGLT2 and cardiovascular events: Why did EMPA-REG Outcomes surprise and what were the likely mechanisms? Naveed Sattar, 1 James McLaren, 1 Søren L Kristensen, 2 David Preiss, 3 John J McMurray 1 1 Institute
More informationDiabete: terapia nei pazienti a rischio cardiovascolare
Diabete: terapia nei pazienti a rischio cardiovascolare Giorgio Sesti Università Magna Graecia di Catanzaro Cardiovascular mortality in relation to diabetes mellitus and a prior MI: A Danish Population
More informationCVD risk assessment using risk scores in primary and secondary prevention
CVD risk assessment using risk scores in primary and secondary prevention Raul D. Santos MD, PhD Heart Institute-InCor University of Sao Paulo Brazil Disclosure Honoraria for consulting and speaker activities
More informationCauses of death in Diabetes
Rates of CV events in Diabetes patients Respiratory4.2 Cancer 7.6 Diabetes 1.3 CV disease 17.3 Causes of death in Diabetes 250 200 150 100 50 0 per 10,000 person-years 97 151 243 Framingham 5 X increase
More informationTechnology appraisal guidance Published: 23 November 2016 nice.org.uk/guidance/ta418
Dapagliflozin in triple therapy for treating type 2 diabetes Technology appraisal guidance Published: 23 November 2016 nice.org.uk/guidance/ta418 NICE 2018. All rights reserved. Subject to Notice of rights
More informationClass Update: Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationEndocrinologist Sweetgrass Endocrinology
Endocrinologist Sweetgrass Endocrinology Sanders, Cummings Ask Justice Department to Investigate Insulin Prices The Department of Justice and the FTC are asked to investigate whether Lilly, Novo Nordisk,
More informationDisclosures. Objectives. Bryan Cardiology Conference DM2 & Cardiovascular Outcome Trials 8/28/2017
Bryan Cardiology Conference DM2 & Cardiovascular Outcome Trials Shannon Wakeley MD Complete Endocrinology 9/2/2017 Disclosures Speakers Bureau: Astra Zeneca, Sanofi, Abbvie, Boehringer-Ingelheim, Medtronic,
More informationManagement of Type 2 Diabetes Mellitus. Heather Corn, MD, MS Endocrinology, Diabetes, and Metabolism
Management of Type 2 Diabetes Mellitus Heather Corn, MD, MS Endocrinology, Diabetes, and Metabolism Disclosures Working for Intermountain Healthcare Some of the views represented are the opinion of ABIM-certified
More informationThe Death of Sulfonylureas? A Review of New Diabetes Medications
The Death of Sulfonylureas? A Review of New Diabetes Medications Kelly Hoenig, Pharm.D., BCPS Cedar Rapids Family Medicine Residency 2/4/17 Objectives Review GLP-1 Agonists, DPP-IV Inhibitors and SGLT-2
More informationSMJ Singapore Medical Journal
SMJ Singapore Medical Journal ONLINE FIRST PUBLICATION Online first papers have undergone full scientific review and copyediting, but have not been typeset or proofread. To cite this article, use the DOIs
More informationType 2 Diabetes. Stopping Smoking. Consider referral to smoking cessation. Consider referring for weight management advice.
Type 2 Diabetes Stopping Smoking Consider referral to smoking cessation BMI > 25 kg m² Set a weight loss target of a 5-10% reduction Consider referring for weight management advice Control BP to
More informationClass Update: Sodium glucose Cotransporter 2 (SGLT2) Inhibitors
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationCanadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC
Canadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC Choosing the Right Agent for your Patient with diabetes: Individualizing type 2 diabetes management in light of the expanding therapies
More informationLa lezione dei trials di safety cardiovascolare. Edoardo Mannucci
La lezione dei trials di safety cardiovascolare Edoardo Mannucci Conflitti di interessi Negli ultimi due anni, E. Mannucci ha ricevuto compensi per relazioni e/o consulenze da: Abbott, AstraZeneca, Boehringer
More informationVariability in drug response: towards more personalized diabetes care Petrykiv, Sergei
University of Groningen Variability in drug response: towards more personalized diabetes care Petrykiv, Sergei IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you
More informationFaculty. Robert S. Busch, MD, FACE Director of Clinical Research Albany Medical Faculty: Community Endocrine Group Albany, NY
Faculty Robert S. Busch, MD, FACE Director of Clinical Research Albany Medical Faculty: Community Endocrine Group Albany, NY 2 Disclosures Robert S. Busch, MD, FACE serves as a speaker for Astra Zeneca,
More informationAn Update on Guidelines and Evidence of the Treatment of Type 2 Diabetes Mellitus
Nevada Academy of Family Physicians 29 th Annual Summer CME Meeting August 3 5, 2018 An Update on Guidelines and Evidence of the Treatment of Type 2 Diabetes Mellitus Presented by: James D. Honeycutt,
More informationPaolo Fornengo SCDU Medicina Interna 3 AOU Città della Salute e della Scienza di Torino
Paolo Fornengo SCDU Medicina Interna 3 AOU Città della Salute e della Scienza di Torino The KID-ney behind the curtain Altered Renal Glucose Control in Diabetes Gluconeogenesis is increased in postprandial
More informationNew Therapies for Type 2 Diabetes
New for Type 2 Diabetes Joshua J. Joseph, MD Assistant Professor of Medicine Division of Endocrinology, Diabetes and Metabolism The Ohio State University Wexner Medical Center Financial Disclosures: None
More informationNew Therapies for Type 2 Diabetes
New for Type 2 Diabetes Joshua J. Joseph, MD Assistant Professor of Medicine Division of Endocrinology, Diabetes and Metabolism The Ohio State University Wexner Medical Center Financial Disclosures: None
More informationHEART FAILURE AND DIABETES MELLITUS: DANGEROUS LIASONS MICHEL KOMAJDA, MD
HEART FAILURE AND DIABETES MELLITUS: DANGEROUS LIASONS MICHEL KOMAJDA, MD Author affiliations: Department of Cardiology, Hôpital Saint Joseph, Paris, France Address for correspondence: Michel Komajda,
More information7 th Munich Vascular Conference
7 th Munich Vascular Conference Secondary prevention of major cardiovascular events in patients with CHD or PAD - What can we learn from EUCLID and COMPASS, evaluating Clopidogrel, Ticagrelor and Univ.-Prof.
More informationDECLARATION OF CONFLICT OF INTEREST
DECLARATION OF CONFLICT OF INTEREST Is there a mortality risk associated with aspirin use in heart failure? Results from a large community based cohort Margaret Bermingham, Mary-Kate Shanahan, Saki Miwa,
More information